Previous studies have indicated that SPARC promotes bone metastasis and epithelial-mesenchymal transition (EMT) in some types of highly metastatic cancers, including melanoma, prostate cancer, and breast cancer [21, 22]. Here, SPARC is linked to Familial prostate cancer.